Yinhua CSI Innovative Drugs Industry ETF(159992) rises 1.54%, with a share increase of 158 million units over the past week

NewTimeSpace (newtimespace.com) News, as of 14:35 on July 20, 2026, Yinhua Innovative Drug ETF (159992) rose 1.54%, with the latest price at 0.86 yuan. Over a longer time frame, as of July 17, 2026, the ETF accumulated a gain of 14.38% over the past month, ranking 3/7 among comparable funds.

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 7.15% and a trading volume of 1.256 billion yuan. Over a longer time frame, as of July 17, the ETF's average daily trading volume over the past week reached 1.830 billion yuan, ranking first among comparable funds.

In terms of scale, Yinhua Innovative Drug ETF saw a significant increase of 177 million yuan in scale month-to-date, with the new scale increase ranking 3/7 among comparable funds. (Data source: Wind)

In terms of shares, Yinhua Innovative Drug ETF experienced a significant increase of 158 million units in share count over the past week, with the new share increase ranking 3/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for Yinhua Innovative Drug ETF was 390 million yuan. Over a longer time frame, within the past five trading days, there were four days of net inflow, attracting a total of 301 million yuan, with an average daily net inflow of 60.1881 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. Yinhua Innovative Drug ETF recorded a net margin financing purchase of 4.9269 million yuan month-to-date, with the latest margin financing balance standing at 700 million yuan. (Data source: Wind)

As of July 17, the net value of Yinhua Innovative Drug ETF rose by 33.93% over the past two years. From the perspective of return capability, as of July 17, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest streak of consecutive up months of 4 months, a maximum cumulative gain during that streak of 53.27%, and an average return of 6.43% in up months. As of July 17, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.88%, ranking in the top 3/7 among comparable funds.

In terms of drawdown, as of July 17, 2026, Yinhua Innovative Drug ETF recorded a drawdown of 0.18% relative to its benchmark over the past six months. The number of days to recover after the drawdown was 37 days, reflecting relatively fast recovery among comparable funds.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which Yinhua Innovative Drug ETF tracks, is only 48.08 times, standing at the 17.9% percentile over the past year. This means the valuation is lower than over 82.1% of the time in the past year, placing it at a historical low.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.